← Eichor
Condition: High Risk Neuroblastoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: High Risk Neuroblastoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
EARLY_Phase 1 · 12 location(s) · C17 Council · NCT06942039Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Phase 1/Phase 2 · 2 location(s) · University of Arizona · NCT06814496Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Phase 3 · 162 location(s) · Children's Oncology Group · NCT03126916High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
Phase 3 · 126 location(s) · St. Anna Kinderkrebsforschung · NCT01704716Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
Phase 1/Phase 2 · 2 location(s) · Roberto Chiarle · NCT06803875A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Phase 2 · 6 location(s) · Nationwide Children's Hospital · NCT05135975N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Phase 2 · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT06528496A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
Phase 2 · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT04936529A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta
Phase N/A · 13 location(s) · RECORDATI GROUP · NCT04253015Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma
Phase N/A · 1 location(s) · Guangzhou Women and Children's Medical Center · NCT06574698A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
Phase 2/Phase 3 · 5 location(s) · Renaissance Pharma Ltd. · NCT07549321Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma
Phase 3 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT06071897GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
Phase 1 · 1 location(s) · Stephan Grupp MD PhD · NCT05650749Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
Phase 2 · 28 location(s) · Giselle Sholler · NCT02559778High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
Phase 3 · 142 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT04221035Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT02605421A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06057948Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neurobla
Phase 1 · 1 location(s) · Jagiellonian University · NCT05272371Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumor
Phase 1 · 1 location(s) · University of Wisconsin, Madison · NCT02508038Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Phase 2 · 3 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT01804634Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma
Phase 1 · 1 location(s) · Marzieh Ebrahimi · NCT06674265Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Ris
Phase 3 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT07375563Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma.
Phase 1 · 2 location(s) · Sun Yat-sen University · NCT06631391Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma
Phase 1 · 1 location(s) · Princess Maxima Center for Pediatric Oncology · NCT06485947Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treat
Phase 1/Phase 2 · 1 location(s) · Fundación de investigación HM · NCT06607692177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
Phase 2 · 5 location(s) · Jakob Stenman · NCT04903899Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07502287Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
NA · 6 location(s) · Dana-Farber Cancer Institute · NCT06831552Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Phase 2 · 25 location(s) · Giselle Sholler · NCT05489887Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed
Phase 3 · 178 location(s) · National Cancer Institute (NCI) · NCT06172296
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.